ArticleCancer research2008
Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors.
Article in Cancer research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 40 citations in OpenAlex.
- Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study).Cancer immunology, immunotherapy : CII · 2013Trial
- Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells.Journal of leukocyte biology · 2016Article
- Different maturation cocktails provide dendritic cells with different chemoattractive properties.Journal of translational medicine · 2015Article
- Correlates between host and viral transcriptional program associated with different oncolytic vaccinia virus isolates.Human gene therapy methods · 2012Article
- Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes.International journal of cancer · 2012Article
- A signature of immune function genes associated with recurrence-free survival in breast cancer patients.Breast cancer research and treatment · 2012Article
- Synthesis and characterization of intrinsically radiolabeled quantum dots for bimodal detection.American journal of nuclear medicine and molecular imaging · 2012Article
- Distinct signatures of the immune responses in low risk versus high risk neuroblastoma.Journal of translational medicine · 2011Article
- Therapeutic cancer vaccines and translating vaccinomics science to the global health clinic: emerging applications toward proof of concept.Omics : a journal of integrative biology · 2011Review
- Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
- Comparison of adjuvant activity of N- and C-terminal domain of gp96 in a Her2-positive breast cancer model.Cell stress & chaperones · 2011Article
- Revisiting cancer immunoediting by understanding cancer immune complexity.The Journal of pathology · 2011Article
- CD4+ T cells inhibit the neu-specific CD8+ T-cell exhaustion during the priming phase of immune responses against breast cancer.Breast cancer research and treatment · 2011Article
- Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure.Journal of translational medicine · 2011Article
- Enhanced tumor therapy using vaccinia virus strain GLV-1h68 in combination with a β-galactosidase-activatable prodrug seco-analog of duocarmycin SA.Cancer gene therapy · 2011Article
- A multiscale systems perspective on cancer, immunotherapy, and Interleukin-12.Molecular cancer · 2010Review
- N-terminally fusion of Her2/neu to HSP70 decreases efficiency of Her2/neu DNA vaccine.Cell stress & chaperones · 2010Article
- Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice.Cancer immunology, immunotherapy : CII · 2010Article
- Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824.Cancer research · 2009Article
- A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity.Journal of immunology (Baltimore, Md. : 1950) · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
We have previously shown T-cell-mediated rejection of the neu-overexpressing mammary carcinoma cells (MMC) in wild-type FVB mice. However, following rejection of primary tumors, a fraction of animals experienced a recurrence of a neu antigen-negative variant (ANV) of MMC (tumor evasion model) after a long latency period. In the present study, we determined that T cells derived from wild-type FVB mice can specifically recognize MMC by secreting IFN-gamma and can induce apoptosis of MMC in vitro. Neu transgenic (FVBN202) mice develop spontaneous tumors and cannot reject it (tumor tolerance model). To dissect the mechanisms associated with rejection or tolerance of MMC tumors, we compared transcriptional patterns within the tumor microenvironment of MMC undergoing rejection with those that resisted it either because of tumor evasion/antigen loss recurrence (ANV tumors) or because of intrinsic tolerance mechanisms displayed by the transgenic mice. Gene profiling confirmed that immune rejection is primarily mediated through activation of IFN-stimulated genes and T-cell effector mechanisms. The tumor evasion model showed combined activation of Th1 and Th2 with a deviation toward Th2 and humoral immune responses that failed to achieve rejection likely because of lack of target antigen. Interestingly, the tumor tolerance model instead displayed immune suppression pathways through activation of regulatory mechanisms that included in particular the overexpression of interleukin-10 (IL-10), IL-10 receptor, and suppressor of cytokine signaling (SOCS)-1 and SOCS-3. These data provide a road map for the identification of novel biomarkers of immune responsiveness in clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.